BioNTech SE (BNTX)
NASDAQ: BNTX · Real-Time Price · USD
106.72
+0.58 (0.55%)
At close: Jun 27, 2025, 4:00 PM
106.08
-0.64 (-0.60%)
After-hours: Jun 27, 2025, 7:56 PM EDT
BioNTech SE Revenue
BioNTech SE had revenue of 182.80M EUR in the quarter ending March 31, 2025, a decrease of -2.56%. This brings the company's revenue in the last twelve months to 2.75B, up 0.61% year-over-year. In the year 2024, BioNTech SE had annual revenue of 2.75B, down -27.96%.
Revenue (ttm)
2.75B EUR
Revenue Growth
+0.61%
P/S Ratio
8.45
Revenue / Employee
405,538 EUR
Employees
6,772
Market Cap
26.28B USD
Revenue Chart
* This company reports financials in EUR.
Revenue History
| Fiscal Year End | Revenue | Change | Growth |
|---|---|---|---|
| Dec 31, 2024 | 2.75B | -1.07B | -27.96% |
| Dec 31, 2023 | 3.82B | -13.49B | -77.94% |
| Dec 31, 2022 | 17.31B | -1.67B | -8.78% |
| Dec 31, 2021 | 18.98B | 18.49B | 3,834.63% |
| Dec 31, 2020 | 482.30M | 373.70M | 344.11% |
| Dec 31, 2019 | Pro | Pro | Pro |
| Dec 31, 2018 | Pro | Pro | Pro |
| Dec 31, 2017 | Pro | Pro | Pro |
| Dec 31, 2016 | Pro | Pro | Pro |
| Dec 31, 2015 | Pro | Pro | Pro |
Sources: Historical revenue is based on company filings submitted to the U.S. Securities and Exchange Commission (SEC). The most recent revenue numbers may be taken from company press releases.
Revenue Definition
Revenue, also called sales, is the amount of money a company receives from its business activities, such as sales of products or services. Revenue does not take any expenses into account and is therefore different from profits.
Full DefinitionRelated Stocks
| Company Name | Revenue |
|---|---|
| UnitedHealth Group | 410.06B |
| Johnson & Johnson | 89.33B |
| Merck & Co. | 63.92B |
| AbbVie | 57.37B |
| AstraZeneca | 54.98B |
| Novartis AG | 53.22B |
| Eli Lilly and Company | 49.00B |
| Novo Nordisk | 43.92B |
BNTX News
- 11 days ago - 5 Stocks To Ride The German Market Rally - Benzinga
- 15 days ago - BioNTech Expands mRNA Cancer Portfolio With CureVac $1.25 Billion All-Stock Deal - Benzinga
- 16 days ago - BioNTech to Buy CureVac in $1.25 Billion Deal. Both Stocks Are Rising. - Barrons
- 16 days ago - BioNTech to acquire CureVac in $1.25 billion all-stock deal - Reuters
- 16 days ago - BioNTech Announces Strategic Transaction to Acquire CureVac in Public Exchange Offer - GlobeNewsWire
- 17 days ago - RFK Jr.'s firing of CDC vaccine advisors 'circumvents science' and could threaten public health, experts say - CNBC
- 17 days ago - Vaccine actions and policy positions under US Health Secretary Kennedy - Reuters
- 18 days ago - Vaccine stocks muted as Wall Street takes 'wait and watch' approach after Kennedy's shake-up - Reuters